Brain

Nexalin Technology Announces Completion of Phases One Through Five of its Virtual Clinic and Digital Ecosystem for HALO™ Clinical Research and Patient Management

AI-Powered Platform Now Fully Operational to Support Data Capture, Remote Monitoring, and Virtual Treatment with HALO™HOUSTON, TX, April 23, 2025...

Vaccinex to Report Promising New Clinical Data Revealing Pepinemab’s Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)

Neoadjuvant treatment with pepinemab appears to induce abundant, mature lymphoid structures that correlate with durable clinical benefit of immunotherapy in...

Nexalin Technology Expresses Strong Support for Health Tech Investment Act to Advance Medicare Reimbursement for AI-Enabled Devices

Proposed bipartisan legislation would expand Medicare reimbursement pathways for AI-enabled medical devices — a framework that supports Nexalin’s Gen-3 HALO...

Moleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025

HOUSTON, April 17, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company...

gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Shown to be Effective in Treating Concussive Symptoms Associated with Mild Traumatic Brain Injuries

ROCKAWAY, N.J., April 17, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced...

error: Content is protected !!